This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and NeuroOne Medical Technologies (NMTC)

Tipranks - Tipranks - Thu May 14, 7:24AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Organigram Global (OGI) and NeuroOne Medical Technologies (NMTC) with bullish sentiments.

Claim 55% Off TipRanks

Organigram Global (OGI)

ATB Cormark Capital Markets analyst Frederico Gomes maintained a Buy rating on Organigram Global today and set a price target of C$2.50. The company’s shares closed last Tuesday at $1.11, close to its 52-week low of $0.96.

According to TipRanks.com, Gomes is a 2-star analyst with an average return of 1.4% and a 57.8% success rate. Gomes covers the Healthcare sector, focusing on stocks such as Green Thumb Industries, Curaleaf Holdings, and Trulieve Cannabis. ;'>

Currently, the analyst consensus on Organigram Global is a Strong Buy with an average price target of $2.51, a 129.2% upside from current levels. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.

See today’s best-performing stocks on TipRanks >>

NeuroOne Medical Technologies (NMTC)

JonesTrading analyst Justin Walsh reiterated a Buy rating on NeuroOne Medical Technologies today and set a price target of $8.00. The company’s shares closed last Tuesday at $4.39.

According to TipRanks.com, Walsh is a 5-star analyst with an average return of 20.4% and a 38.1% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Praxis Precision Medicines. ;'>

Currently, the analyst consensus on NeuroOne Medical Technologies is a Strong Buy with an average price target of $11.33, which is a 164.7% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $8.00 price target.

Read More on OGI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).